ArticleInternational journal of rheumatic diseases2025
Get OUT: Factors Associated With a Longer Length of Stay in Patients Admitted With an Acute Gout Flare, and the Effects of Anakinra on Length of Stay.
Article in International journal of rheumatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Impact of Disease Severity and Age on Outcomes After Laparoscopic Versus Open Appendectomy: A Single-Center Retrospective Cohort Study.Life (Basel, Switzerland) · 2026Article
- Get OUT: Factors Associated With a Longer Length of Stay in Patients Admitted With an Acute Gout Flare, and the Effects of Anakinra on Length of Stay.International journal of rheumatic diseases · 2025Article
- Postoperative abdominal wall actinomycosis mimicking malignancy: a case report and literature review.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAcute gout flares (AGF) are a significant burden to healthcare systems globally, due to the prolonged length of stay (LOS). The study's aim was to audit patients admitted to our facility with AGF, then re-audit after the introduction of interleukin-1 receptor antagonist anakinra in select patients to assess whether it would result in a reduced LOS.
methodsA single-center retrospective audit was conducted on 62 hospitalizations for AGF in 2019 that met inclusion criteria. Data on patient demographics, comorbidities, and clinical parameters (number of joints involved, C-reactive protein (CRP), urate levels, and tophi) were analyzed using multivariable Poisson regression models to determine predictors of LOS. We then compared patients that received anakinra in 2020 (n = 7) with a historical control group (n = 13).
resultsThe average LOS in 2019 for AGF was 3.36 days (1.22-4.28). CRP, prior use of allopurinol, and impaired mobility levels were significant predictors of prolonged LOS, with respective coefficients of 0.0036 (95% CI: 0.0023-0.0050, p < 0.0001), 0.321 (95% CI: 0.043-0.599, p = 0.023), and 0.708 (95% CI: 0.416-1.000, p < 0.0001). When CRP was treated as a controlled variable, patients treated in 2020 with anakinra demonstrated a 0.493-day reduction in LOS compared to the control group, which was statistically significant (p = 0.043).
conclusionCRP levels, allopurinol use, and impaired mobility are key predictors of prolonged LOS in AGF. Although the use of anakinra shows promise in reducing LOS and costs, larger studies are needed to confirm its efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.